Q1 2027 Orchid Pharma Ltd Earnings Call Transcript
Key Points
- Revenue from operations grew 15% year-over-year to INR304 crores in Q1 FY27, indicating a recovery from the challenging prior year.
- Gross margin improved by approximately 3 percentage points to 33% in Q1 FY27, up from 30% in the same quarter last year.
- EBITDA more than doubled to INR25 crores in Q1 FY27, compared to INR10 crores in Q1 FY26, reflecting better operational efficiency.
- Exblifep volumes in Europe are growing strongly, with a 50% quarter-over-quarter increase in Q1 FY27, following 300% and 170% growth in previous quarters.
- The Cefiderocol project remains on schedule for commissioning by December 2026, with validation batches planned for early 2027.
- The 7-ACA project is on track for commissioning and first commercial batch by March 2027, which will provide significant backward integration advantages.
- The merger with Dhanuka Laboratories is expected to yield integration benefits, with initial savings visible in the next financial year.
- The AMS business EBITDA drag has reduced significantly to approximately INR50 lakhs in Q1 FY27, down from previous levels.
- Advanced discussions are underway for Exblifep partnerships in South America, Mexico, Philippines, Thailand, Morocco, and Australia, expanding global reach.
- The company has a diversified portfolio of 20-25 cephalosporin products, differentiating it from competitors who focus on only a few high-volume products.
- The cephalosporin industry continues to face overcapacity and cutthroat competition, leading to pricing pressure and margin compression.
- Cefixime, a key product, is under maximum stress with respect to margins, particularly in the rest of the world markets.
- The company remains cautious about a straight-line recovery, noting that pricing and demand conditions in core markets remain competitive.
- The Middle East and Africa launch of Exblifep has been delayed due to regional conflict, impacting commercial rollout timelines.
- The 7-ACA project involves significant execution risks, including a scale-up from pilot plant to commercial scale (20 to 800 times), which may lead to longer ramp-up times.
- The company has not provided specific revenue guidance for FY27, indicating uncertainty about future growth.
- The Cefiderocol project faces potential delays in regulatory approvals, with the first product approval expected only 6-9 months after facility readiness.
- The company's reliance on a Chinese CMO for Exblifep supply initially may expose it to supply chain risks.
- The US formulation strategy is long-term (until 2030) and will not provide near-term revenue contributions.
- The company's PLI benefits for the 7-ACA project may be limited to two years, with no guarantee of extension, adding financial uncertainty.
Ladies and gentlemen, good day, and welcome to Orchid Pharma Limited Q1 and FY '27 earnings conference call hosted by Systematix Shares & Stocks. (Operator Instructions) This conference call may contain forward-looking statements about the company, which are based on beliefs, opinion and expectation of the company as on date of this call. These statements are not guarantee of future performance and involve risks and uncertainties that are difficult to predict.
I now hand the conference over to Ms. Loveleen Bagga from Systematix Shares & Stocks. Thank you, and over to you, Ms. Loveleen.
Thank you, Danish. Good evening, everyone. On behalf of Systematix Institutional Equities, I welcome you all to the Q1 FY '27 earnings call of Orchid Pharma. We thank the Orchid Pharma management for giving us an opportunity to host the call. Today, we have with us the senior management of the company represented by Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole-Time Director; Mr. Nishant
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
